ROQA.F Stock Overview
A material biotech company, engages in the development of medicines for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Roquefort Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.049 |
| 52 Week High | UK£0.10 |
| 52 Week Low | UK£0.049 |
| Beta | 0.049 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -59.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| ROQA.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -0.1% | 0.8% |
| 1Y | n/a | 21.7% | 33.4% |
Return vs Industry: Insufficient data to determine how ROQA.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how ROQA.F performed against the US Market.
Price Volatility
| ROQA.F volatility | |
|---|---|
| ROQA.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ROQA.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ROQA.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 10 | Ajan Reginald | www.roquefortplc.com |
Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy, toxicology studies, and orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and natural killer cell-mediated anti-cancer action. The company was incorporated in 2020 and is based in London, the United Kingdom.
Roquefort Therapeutics plc Fundamentals Summary
| ROQA.F fundamental statistics | |
|---|---|
| Market cap | US$6.23m |
| Earnings (TTM) | -US$2.07m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.0x
P/E RatioIs ROQA.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ROQA.F income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£16.00k |
| Gross Profit | -UK£16.00k |
| Other Expenses | UK£1.53m |
| Earnings | -UK£1.54m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.012 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 12.4% |
How did ROQA.F perform over the long term?
See historical performance and comparison